Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Audio By Carbonatix

SAN FRANCISCO--(BUSINESS WIRE)--Jan 5, 2026--

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260105543597/en/

CONTACT: Media

CorporateComms@vir.bioInvestors

IR@vir.bio

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS STEM CELLS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH SCIENCE ONCOLOGY

SOURCE: Vir Biotechnology, Inc.

Copyright Business Wire 2026.

PUB: 01/05/2026 04:05 PM/DISC: 01/05/2026 04:06 PM

http://www.businesswire.com/news/home/20260105543597/en